[HTML][HTML] Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients
M Oyaert, MA De Scheerder, S Van Herrewege… - Frontiers in …, 2022 - frontiersin.org
Background Immunocompromised patients are at increased risk of severe COVID-19 and
impaired vaccine response. In this observational prospective study, we evaluated …
impaired vaccine response. In this observational prospective study, we evaluated …
mRNA COVID-19 vaccine booster fosters B-and T-cell responses in immunocompromised patients
E Azzolini, C Pozzi, L Germagnoli… - Life Science …, 2022 - life-science-alliance.org
SARS-CoV-2 vaccination has proven effective in inducing an immune response in healthy
individuals and is progressively us allowing to overcome the pandemic. Recent evidence …
individuals and is progressively us allowing to overcome the pandemic. Recent evidence …
[HTML][HTML] Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a …
P Bergman, O Blennow, L Hansson, S Mielke… - …, 2021 - thelancet.com
Background Patients with immunocompromised disorders have mainly been excluded from
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …
[HTML][HTML] Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases
RM Dayam, JC Law, RL Goetgebuer, GYC Chao… - JCI insight, 2022 - ncbi.nlm.nih.gov
BACKGROUND Limited information is available on the impact of immunosuppressants on
COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID) …
COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID) …
[HTML][HTML] Interferon-gamma release assays outcomes in healthy subjects following BNT162b2 mRNA COVID-19 vaccination
E Kurteva, G Vasilev, K Tumangelova-Yuzeir… - Rheumatology …, 2022 - Springer
The pathogenesis of COVID-19 involves both humoral and cellular immunological
responses, with cell-mediated immunity being discussed as the primary and most effective …
responses, with cell-mediated immunity being discussed as the primary and most effective …
[HTML][HTML] Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies
D Amodio, A Ruggiero, M Sgrulletti, C Pighi… - Frontiers in …, 2021 - frontiersin.org
Mass SARS-Cov-2 vaccination campaign represents the only strategy to defeat the global
pandemic we are facing. Immunocompromised patients represent a vulnerable population at …
pandemic we are facing. Immunocompromised patients represent a vulnerable population at …
[HTML][HTML] Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and-experienced subjects: impact …
S Desmecht, A Tashkeev, M El Moussaoui… - Frontiers in …, 2022 - frontiersin.org
Background Understanding and measuring the individual level of immune protection and its
persistence at both humoral and cellular levels after SARS-CoV-2 vaccination is mandatory …
persistence at both humoral and cellular levels after SARS-CoV-2 vaccination is mandatory …
[HTML][HTML] Mini review immunological consequences of immunization with COVID-19 mRNA vaccines: preliminary results
A Lombardi, G Bozzi, R Ungaro, S Villa… - Frontiers in …, 2021 - frontiersin.org
Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based
vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data …
vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data …
[HTML][HTML] CD19+ IgD+ CD27-naive B cells as predictors of humoral response to COVID 19 mRNA vaccination in immunocompromised patients
E Schulz, I Hodl, P Forstner, S Hatzl… - Frontiers in …, 2021 - frontiersin.org
Immunocompromised patients are considered high-risk and prioritized for vaccination
against COVID-19. We aimed to analyze B-cell subsets in these patients to identify potential …
against COVID-19. We aimed to analyze B-cell subsets in these patients to identify potential …
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator …
MB Moor, F Suter-Riniker, MP Horn… - The Lancet …, 2021 - thelancet.com
Background B-cell-depleting therapies increase the risk of morbidity and mortality due to
COVID-19. Evidence-based SARS-CoV-2 vaccination strategies for patients on B-cell …
COVID-19. Evidence-based SARS-CoV-2 vaccination strategies for patients on B-cell …
相关搜索
- sars cov immunocompromised patients
- humoral response immunocompromised patients
- humoral response mrna vaccination
- mrna vaccination immunocompromised patients
- sars cov mrna vaccines
- sars cov immune responses
- mrna vaccine immune responses
- sars cov healthy controls
- healthy controls immunocompromised patients
- sars cov covid 19
- vaccine booster immunocompromised patients
- sars cov inflammatory diseases
- safety and efficacy immunocompromised patients
- sars cov kinetics and persistence
- sars cov breakthrough infections
- sars cov booster dose